Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)

NCT04380519 is registered in ClinicalTrials.gov with R-Pharm International, LLC as lead sponsor.

NCT NCT04380519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04380519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)
Lead sponsor
R-Pharm International, LLC
Phase
Phase 2/3
Overall status
Completed
Start date
April 23, 2020
Completion date
July 24, 2020
Enrollment
372 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19